Effect of Nebulized Magnesium Sulphate in Terms of the In-HospitalOutcome of Patients Admitted with Acute Exacerbation of ChronicObstructive Pulmonary disease

Authors

Abstract

Objective: To evaluate the efficacy of Magnesium Sulphate (MgSO4) with the conventional treatment in acute exacerbation chronic obstructive pulmonary disease (AECOPD)

Methods

: This Quasi-experimental study was conducted in Department of Internal Medicine from July 2020 to July 2022. The study involved 160 patients in total. There were two groups of patients. Group Awas nebulized with 250mg of MgSO4 fourtimes a day along with conventionaltreatment. GroupB was given only conventionaltreatment.Conventionaltreatment included oxygen inhalation, anti-cholinergic and beta-2 agonist nebulization, intravenous steroids, and intravenous antibiotics. Both groups were followed for five days to assess the effect of nebulized magnesium.

Results

 : Group Arequired assisted ventilation for 2–3 days for 28% of the subjects (22 patients out of 80), while group B required it for 81% of the subjects (65 patients out of 80). In addition, only 9% of patients in group Aand 8% of patients in group B needed assisted ventilation for four to five days. In comparison to group A, which had 33% of patients discharged on the fourth day and 20% on the fifth day or later, group B saw 53% of patients discharged on the fourth day and 20% on the fifth day or later. The results showed that PCO2 and peak expiratory flow rate (PEFR) have a significant variance between group Aand group B and values have no significant variance between group Aand group B on the first day and the last day.

Conclusion

 : Nebulized supplementation improves in-hospital outcomes in patients presenting with acute exacerbation of COPD as compared to the patients not receiving nebulized magnesium sulphate.

Keywords:

Acute exacerbation, Chronic Obstructive Pulmonary Disease (COPD), Nebulized Magnesium Sulphate

Published

2024/02/28

Issue

Vol. -ISSUE 1
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This is an open-access journal and all the published articles / items are distributed under the terms of the  Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com